The 20 Best Pineoblastoma Doctors Near Me in Washington, DC

Eglal Shalaby-Rana, MD, is a radiologist in the Division of Diagnostic Imaging and Radiology at Children's National Hospital. She is the director of performance improvement. Dr. Rana is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Hirschsprung Disease, Scoliosis, Knock Knees, and Biliary Atresia. Dr. Rana is board certified in Pediatric Radiology: American Board Of Radiology, 1995 and Diagnostic Radiology: American Board Of Radiology, 1987.

"Eugene (Gene) Hwang, MD, is chief of the Division of Oncology at Children’s National Hospital in Washington, D.C. He is also part of the Children's National Hospital pediatric neuro-oncology team, focusing on treating children with brain tumors. Dr. Hwang has developed and led many novel early phase therapeutic clinical trials with a focus on immunotherapeutic trials, and he also leads trials focused on gene therapy and new, targeted agents. He is the site Principal Investigator of the Pediatric Brain Tumor Consortium, where he is the co-chair of the Immunotherapy Working Group. He serves on grant review committees and on the scientific advisory boards of several large foundations. For each patient, Dr. Hwang carefully considers the best possible options for treatment, trying new, cutting edge treatments coupled with the best available known therapies. Dr. Hwang is not only dedicated to finding a cure for cancer, but also to making the current treatments as safe as possible for children: ""We often focus on curing the children - that's the number one goal - but we also need to pay attention to the toxicity of these treatments, and what quality of life the children will have after treatment."" Dr. Hwang is involved in several international efforts to study how to best mitigate treatment side effects. In the meantime, Dr. Hwang makes sure he is doing everything he can to combat pain, dizziness, fatigue and other common side effects of cancer treatments by leveraging the multidisciplinary team approach of Children's National. He sees this as something the organization does exceptionally well, and thinks that having so many people focus on a single patient in a single visit is crucial to well-being during cancer treatment.". Dr. Hwang is rated as an Advanced provider by MediFind in the treatment of Pineoblastoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Pineocytoma, Glioma, Medulloblastoma, and Pineoblastoma. Dr. Hwang is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2005.

Roger Packer is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. Dr. Packer is rated as an Advanced provider by MediFind in the treatment of Pineoblastoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, and Gliomatosis Cerebri.

Brian R. Rood, MD, is the director of clinical neuro-oncology and the medical director of the Brain Tumor Institute at Children's National Hospital. Dr. Rood is also a principal investigator in the Center for Cancer and Immunology Research at Children's National Research Institute and a professor of pediatrics at the George Washington University School of Medicine and Health Sciences and adjunct professor at the Fralin Biomedical Research Institute at Virginia Tech. He received a Bachelor of Arts in English Literature from The Pennsylvania State University and completed medical school at Jefferson Medical College. He completed his pediatric residency training at the University of Vermont. Dr. Rood received his pediatric hematology/oncology training at Children's National. He joined the faculty of Children’s National in 2002 after completing a fellowship in pediatric hematology/oncology, as well as a research fellowship in the molecular biology of brain tumors, both at Children’s National and Children’s National Research Institute. Currently, Dr. Rood’s research focuses on the application of proteomics in cancer biology investigation, neoantigen identification and biomarker development. He has also been studying the contribution of germline microsatellite genotypes to pediatric brain tumor predisposition. He currently serves as the executive co-chair of the Children’s Brain Tumor Network, an international consortium of 28 institutions that maintains the world’s largest pediatric brain tumor tissue and data repository, which are freely provided to the research community to support the development of groundbreaking clinical trials through data-driven precision medicine. Dr. Rood has two children. His favorite pastimes include designing and building furniture, sailing, reading, and playing the mandolin. Dr. Rood is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Diffuse Midline Glioma H3 K27M-Mutant. Dr. Rood is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002 and Pediatrics: American Board Of Pediatrics, 1998.

Hannah Kinoshita, MD, is an oncologist in the Division of Oncology in the Center for Cancer and Blood Disorders. Her research interests include cellular immunotherapy for high-risk hematologic malignancies. Dr. Kinoshita is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. Her clinical expertise encompasses Multisystem Inflammatory Syndrome in Children (MIS-C), Acute Lymphoblastic Leukemia (ALL), Leukemia, Medulloblastoma, and Bone Marrow Transplant. Dr. Kinoshita is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2023 and American Board Of Pediatrics, 2018.

Adriana Sheridan is a Pediatrics provider practicing medicine in Washington, Washington, D.c.. She has been practicing medicine for over 20 years. Dr. Sheridan is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Pediatric Low-Grade Glioma (pLGG), and Glioma. Dr. Sheridan is board certified in Pediatrics: American Board Of Pediatrics, 2024, Pediatric Hematology-Oncology: American Board Of Pediatrics, 2021, and The Royal College Of Physicians And Surgeons Of Canada, 2015.

Jeffrey Dome, MD, PhD, is senior vice president of the Cancer and Blood Disorders Center at Children’s National Hospital in Washington, D.C. He is professor of pediatrics at the George Washington University School of Medicine and Health Sciences and the Thomas Willson and Lenore Williams McKnew professor of pediatric oncology. Dr. Dome received his medical degree from the University of Pennsylvania School of Medicine and PhD degree in medicine from Erasmus University in Rotterdam. He completed a residency in pediatrics at Yale-New Haven Hospital and completed a fellowship in pediatric hematology/oncology at Johns Hopkins Hospital. After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee for more than a decade. He is presently on the Scientific Council of the COG, the editorial board of Pediatric Blood and Cancer, and is past chair of the American Board of Pediatrics Subboard of Hematology/Oncology. Dr. Dome serves on numerous medical advisory boards for cancer foundations and currently is the North American Continental President of the International Society of Pediatric Oncology (SIOP). He has authored more than 200 articles, books, letters and chapters on pediatric cancer. Dr. Dome is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Adult Soft Tissue Sarcoma, Nephrectomy, and Bone Marrow Aspiration. Dr. Dome is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 1998.

Lindsay Kilburn, MD, comes to Children's National Hospital from Texas Children’s Hospital in Houston, TX, where she was an assistant professor of pediatrics in the neuro-oncology and pharmacology programs. Dr. Kilburn graduated with a degree in Environmental Sciences from the University of Virginia. After graduating from Eastern Virginia Medical School, she completed her pediatric training at the Children’s Hospital of The King’s Daughters in Norfolk, VA, and her hematology/oncology fellowship at Texas Children’s Hospital/Baylor College of Medicine in Houston, TX. She also has received training in pharmacology from both Thomas Jefferson University in Philadelphia and the Baylor College of Medicine in Houston. Dr. Kilburn is an associate professor, pediatrics at George Washington University School of Medicine. Her research focuses on the development and evaluation of new therapeutic agents for children with pediatric brain tumors through clinical trials. She is committed to the improvement of palliative and supportive care. Dr. Kilburn grew up outside of Philadelphia and is married with young twins. Outside of work, she enjoys sailing, hiking, and traveling with her family. Dr. Kilburn is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, and Optic Glioma. Dr. Kilburn is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009 and Pediatrics: American Board Of Pediatrics, 2004.

Holly Meany, MD, is a pediatric oncologist and director of the Solid Tumor Program at Children’s National Hospital. She also serves as an associate professor of pediatrics at George Washington University. Dr. Meany is dedicated to finding better treatments for children with cancer through research and clinical care. Her work focuses on developing new therapies for pediatric solid tumors. She designs and leads early-phase clinical trials to test promising treatments and understand how they work in children. Dr. Meany has played a key role in several national studies, including large trials for neuroblastoma, a type of childhood cancer. She recently led an international study for children with newly diagnosed non-high-risk neuroblastoma and is currently helping to develop the next high-risk neuroblastoma trial, both through the Children’s Oncology Group. Dr. Meany is also exploring innovative approaches like immunotherapy—using the body’s own immune system to fight cancer. She has led international studies using specialized T cells to treat patients with relapsed solid tumors and is now working on combining these novel T cells with CAR T-cell therapy for children with relapsed cancers. In addition to her research, Dr. Meany is passionate about training the next generation of pediatric cancer specialists. As director of the Pediatric Hematology-Oncology Fellowship Program at Children’s National, she mentors and supports future leaders in the field. Dr. Meany is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Osteosarcoma, and Mastoidectomy. Dr. Meany is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

David Jacobsohn, MD, ScM, MBA, is the division chief of the Blood and Marrow Transplantation Program at Children’s National Hospital and full professor of Pediatrics at the George Washington University. He leads a program of upwards of 70 pediatric transplants per year. The program performs transplants in patients with malignant and non-malignant conditions, and has expertise with all stem cell sources including haplo-identical transplants. His expertise is in graft-versus-host disease (GvHD) clinical trials: reducing incidence of GvHD as well as novel therapies for GvHD. He has more than 10 years of experience in clinical research in pediatric GvHD. His work has included the study of novel drugs for chronic GvHD, classification criteria for chronic GvHD, and risk factor stratification in pediatric chronic GvHD. He is active in the BMT community at a national level. Examples of some current and prior roles include head of the GVHD committee for the Pediatric Blood and Marrow Transplant Consortium, member-at-large of the that Consortium, member of the Children’s Oncology Group Stem Cell Transplant Committee, member of the Clinical Trials Network State of the Science Pediatric Advisory Group. Dr. Jacobsohn has been instrumental in growing the capabilities of the Blood and Marrow Transplant Program. For example, for the last five years the program is one of the few pediatric programs performing alpha/beta T cell depletion for haploidentical transplants. This novel method for GVHD prevention has significantly improved the outcome of haploidentical BMT at Children’s National. Additionally, he has been involved with the deployment of gene therapy for hemoglobinopathies. He successfully led Children’s National to become the first program in the country to collect stem cells for a commercial sickle cell gene therapy treatment. Dr. Jacobsohn is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Hemoglobinopathy, Anemia, Sickle Cell Disease, and Bone Marrow Transplant. Dr. Jacobsohn is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002 and Pediatrics: American Board Of Pediatrics, 1999.